Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting

Future Oncology

Volumn 10, Issue 10, 2014, Pages 1741-1750

  Procopio, Giuseppe ^a   Derosa, Lisa ^b   Gernone, Angela ^c   Morelli, Franco ^d   Sava, Teodoro ^e   Zustovich, Fable ^f   De Giorgi, Ugo ^g   Ferrari, Vittorio ^h   Sabbatini, Roberto ⁱ   Gasparro, Donatello ^j   Felici, Alessandra ^k   Burattini, Luciano ^l   Calvani, Nicola ^m   Lo Re, Giovanni ⁿ   Banna, Giuseppe ^o   Pia Brizzi, Maria ^p   Rizzo, Mimma ^q   Ciuffreda, Libero ^r   Iacovelli, Roberto ^s   Ferraù, Francesco ^t   Taibi, Eleonora ^u   Bracarda, Sergio ^v   Porta, Camillo ^w   Galligioni, Enzo ^x   Contu, Antonio ^y   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c POLICLINICO   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF VERONA   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^h SPEDALI CIVILI   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j UNIVERSITY HOSPITAL OF PARMA   (Italy)

^k REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^l OSPEDALI RIUNITI   (Italy)

^m Division of Medical Oncology   (Italy)

ⁿ S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^o CANNIZZARO HOSPITAL   (Italy)

^p SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^q CARDARELLI HOSPITAL   (Italy)

^r MOLINETTE HOSPITAL   (Italy)

^s SAPIENZA UNIVERSITY OF ROME   (Italy)

^t San Vincenzo Hospital   (Italy)

^u Humanitas Centro Catanese di Oncologia SpA   (Italy)

^v IRCCS POLICLINICO SAN DONATO   (Italy)

^w FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^x SANTA CHIARA HOSPITAL   (Italy)

^y Neurology Unit   (Italy)

more..

Author keywords

community practice; renal cell carcinoma; second line treatment; sorafenib; targeted agents; tyrosine kinase inhibitors

Indexed keywords

EVEROLIMUS; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ADULT; AGED; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL PRACTICE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84907940395     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.48     Document Type: Review

References (30)

1. Escudier B. Signaling inhibitors in metastatic renal cell carcinoma. Cancer J. 14(5), 325-329 (2008).
2. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
3. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27(20), 3312-3318 (2009).
4. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell cancer. N. Engl. J. Med. 356(2), 115-124 (2007).
5. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116(18), 4256-4265 (2010).
6. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa 2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
7. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
8. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
9. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011); erratum: 380(9856), 1818 (2012).
10. Motzer RJ, Nosov D, Eisen T et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase 3, randomized, open-label, multicenter trial. J. Clin. Oncol. 30(Suppl.), Abstract 4501 (2012).
11. Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon alfa 2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(8), 1280-1289 (2009).
12. Motzer RJ, Eisen T, Hutson TE et al. Overall survival results from a Phase III study of tivozanib hydrochloride vs sorafenib in patients with renal cell carcinoma. J. Clin. Oncol. 31(Suppl. 6), Abstract 350 (2013).
13. Hutson TE, Escudier B, Esteban E et al. Temsirolimus vs sorafenib as second-line therapy in metastatic renal cell carcinoma: Phase 3 results from the INTORSECT trial. Presented at: European Society for Medical Oncology Congress. Vienna, Austria, 28 September-2 October 2012 (Abstract LBA22).
14. Rini BI, Szczylik C, Tannir NM et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized double-blind, placebo-controlled, Phase 2 study. Cancer 118(24), 6152-6161 (2012).
15. Hutson TE, Gallardo J, Lesovoy V et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 31(Suppl. 6), Abstract LBA348 (2013).
16. Bellmunt J, Negrier S, Escudier B, Awada A, Aapro M. The medical treatment of metastatic renal cancer in the elderly: Position paper of a SIOG taskforce. Crit. Rev. Oncol. Hematol. 69(1), 64-72 (2009).
17. Jäger D, Guo J, Korbenfeld E et al. Sorafenib in patients with renal cell carcinoma (RCC) and baseline hypertension or diabetes: Subanalysis of the non-interventional PREDICT study. Ann. Oncol. 23(Suppl. 9), ix279 (2012) (Abstract 844P).
18. Procopio G, Verzoni E, Testa I, Nicolai N, Salvioni R, DeBraud F. Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther. Adv. Urol. 4(6), 303-313 (2012).
19. Procopio G, Bellmunt J, Dutcher J et al. Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis. Br. J. Cancer 108(2), 311-318 (2013).
20. Zustovich F, Lombardi G, Farina P. Treating patients with metastatic renal cell carcinoma: An escape from Phase III. Expert Rev. Anticancer. Ther. 12(7), 919-927 (2012).
21. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-Alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
22. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-Targeted agents: Results from a large, multicenter study. J. Clin. Oncol. 27(34), 5794-5799 (2009).
23. Heng DYC, Choueiri TK, Lee JL et al. A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. J. Clin. Oncol. 30(Suppl. 5), Abstract 353 (2012).
24. Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5), 1272-1280 (2010).
25. Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU ARCCS) expanded-Access study: A large open-label study in diverse community settings. Ann. Oncol. 22(8), 1812-1823 (2011).
26. Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: Subset analysis from a randomized trial. J. Natl Cancer Inst. 100(20), 1454-1463 (2008).
27. Choueiri TK, Duh MS, Clement J et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: Effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 105(9), 1247-1254 (2010).
28. Iacovelli R, Carteni G, Sternberg CN et al. Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort. Eur. J. Cancer 49(9), 2134-2142 (2013).
29. Procopio G. Role of sorafenib in renal cell carcinoma: Focus on elderly patients. Expert Rev. Anticancer. Ther. 11(11), 1689-1692 (2011).
30. Zustovich F, Novara G. Advanced kidney cancer: Treating the elderly. Expert Rev. Anticancer. Ther. 13(12), 1389-1398 (2013).